Lapatinib plus trastuzumab extend lives of HER2-positive breast cancer patients

[News]

Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center.

More... (http://www.news-medical.net/news/20091212/Lapatinib-plus-trastuzumab-extend-lives-of-HER2-positive-breast-cancer-patients.aspx)